文献速递神经肿瘤

复发高级别胶质瘤的再照射对比全身治疗对比联合治疗:生存与毒性的系统综述与荟萃分析

Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
PubMed 文献 · J Neurooncol · 2023-09-21

该系统综述与荟萃分析纳入31项研究共2084例复发高级别胶质瘤患者,比较再照射、全身治疗及联合治疗的疗效与毒性。联合治疗较全身治疗改善无进展生存(HR 0.57)和总生存(HR 0.73),3级及以上不良事件无差异;联合治疗较再照射改善无进展生存(HR 0.52)和总生存(HR 0.69);贝伐珠单抗联合再照射较再照射改善无进展生存(HR 0.46)和总生存(HR 0.42)并减少放射性坏死(RR 0.17)。

要点

  • 联合治疗较全身治疗改善无进展生存(HR 0.57)和总生存(HR 0.73),3级及以上不良事件无差异。
  • 联合治疗较再照射改善无进展生存(HR 0.52)和总生存(HR 0.69)。
  • 贝伐珠单抗联合再照射较再照射改善无进展生存(HR 0.46)和总生存(HR 0.42)并减少放射性坏死(RR 0.17)。

核心结论

  • 对于复发高级别胶质瘤患者,联合治疗较单独再照射或单独全身治疗可能改善总生存和无进展生存,且毒性可接受。
  • 特别是贝伐珠单抗联合再照射可预防性减少放射性坏死。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Scopus、Embase和CENTRAL数据库。
  • 纳入31项研究(3项随机、28项非随机),共2084例参与者。
  • 纳入比较组包括:再照射对比全身治疗、联合治疗对比全身治疗、联合治疗对比再照射、贝伐珠单抗为基础的联合治疗对比再照射联合或不联合非贝伐珠单抗为基础的全身治疗。
  • 采用随机效应模型进行荟萃分析,使用GRADE评估证据确定性。
  • 注册号:CRD42022291741。

主要发现

  • 联合治疗对比全身治疗组:联合治疗改善无进展生存(HR 0.57,95%CI 0.41-0.79;低确定性)和总生存(HR 0.73,95%CI 0.56-0.95;低确定性),3级及以上不良事件无差异(RR 1.03,95%CI 0.57-1.86;极低确定性)。
  • 联合治疗对比再照射组:联合治疗改善无进展生存(HR 0.52,95%CI 0.38-0.72;低确定性)和总生存(HR 0.69,95%CI 0.52-0.93;低确定性)。
  • 贝伐珠单抗为基础的联合治疗对比再照射联合或不联合非贝伐珠单抗为基础的全身治疗组:加用贝伐珠单抗改善无进展生存(HR 0.46,95%CI 0.27-0.77;低确定性)和总生存(HR 0.42,95%CI 0.24-0.72;低确定性),并减少放射性坏死(RR 0.17,95%CI 0.06-0.48;低确定性)。

临床怎么用

  • 作者认为,对于复发高级别胶质瘤患者,联合治疗较单独再照射或单独全身治疗可能改善总生存和无进展生存,且毒性可接受。
  • 作者认为,特别是将贝伐珠单抗与再照射联合可预防性减少放射性坏死。

局限性

  • 纳入的31项研究中仅3项为随机研究,28项为非随机研究。
  • 各项结局的证据确定性为低或极低(GRADE分级)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This review compares reirradiation (reRT), systemic therapy and combination therapy (reRT & systemic therapy) with regards to overall survival (OS), progression-free survival (PFS), adverse effects (AEs) and quality of life (QoL) in patients with recurrent high-grade glioma (rHGG). METHODS: A search was performed on PubMed, Scopus, Embase and CENTRAL. Studies reporting OS, PFS, AEs and/or QoL and encompassing the following groups were included; reirradiation vs systemic therapy, combination therapy vs systemic therapy, combination therapy vs reRT, and bevacizumab-based combination therapy vs reRT with/without non-bevacizumab-based systemic therapy. Meta-analyses were performed utilising a random effects model. Certainty of evidence was assessed using GRADE. RESULTS: Thirty-one studies (three randomised, twenty-eight non-randomised) comprising 2084 participants were included. In the combination therapy vs systemic therapy group, combination therapy improved PFS (HR 0.57 (95% CI 0.41-0.79); low certainty) and OS (HR 0.73 (95% CI 0.56-0.95); low certainty) and there was no difference in grade 3 + AEs (RR 1.03 (95% CI 0.57-1.86); very low certainty). In the combination therapy vs reRT group, combination therapy improved PFS (HR 0.52 (95% CI 0.38-0.72); low certainty) and OS (HR 0.69 (95% CI 0.52-0.93); low certainty). In the bevacizumab-based combination therapy vs reRT with/without non-bevacizumab-based systemic therapy group, adding bevacizumab improved PFS (HR 0.46 (95% CI 0.27-0.77); low certainty) and OS (HR 0.42 (95% CI 0.24-0.72; low certainty) and reduced radionecrosis (RR 0.17 (95% CI 0.06-0.48); low certainty). CONCLUSIONS: Combination therapy may improve OS and PFS with acceptable toxicities in patients with rHGG compared to reRT or systemic therapy alone. Particularly, combining bevacizumab with reRT prophylactically reduces radionecrosis. REGISTRATION: CRD42022291741.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Marwah R, Xing D, Squire T, et al. Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity. J Neurooncol. 2023. PMID: 37733174. doi:10.1007/s11060-023-04441-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。